TREATMENT OF POLYARTERITIS-NODOSA RELATED TO HEPATITIS-B VIRUS WITH INTERFERON-ALPHA AND PLASMA EXCHANGES

被引:95
作者
GUILLEVIN, L
LHOTE, F
SAUVAGET, F
DEBLOIS, P
ROSSI, F
LEVALLOIS, D
POURRAT, J
CHRISTOFOROV, B
TREPO, C
机构
[1] HOP LARIBOISIERE,DEPT INTERNAL MED,F-75475 PARIS,FRANCE
[2] CTR HOSP BLOIS,DEPT INTERNAL MED,BLOIS,FRANCE
[3] CTR HOSP VENDOME,DEPT INTERNAL MED,VENDOME,FRANCE
[4] HOP PURPAN,DEPT NEPHROL,TOULOUSE,FRANCE
[5] HOP COCHIN,DEPT INTERNAL MED,F-75674 PARIS,FRANCE
[6] HOP HOTEL DIEU,HEPATOGASTROENTEROL UNIT,LYON,FRANCE
[7] HOP HOTEL DIEU,INSERM,U271,HEPATITIS RES UNIT,LYON,FRANCE
关键词
D O I
10.1136/ard.53.5.334
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives-To test the effectiveness of and tolerance to interferon-alpha 2b (INFa2b) in association with plasma exchanges for the treatment of polyarteritis nodosa (PAN) related to hepatitis B virus (HBV). Methods-A prospective, non blinded, multicentre trial was carried out in which patients with multisystemic HBV-related PAN were included. Each patient received the association of INFa2b and plasma exchanges. The end point of the study was control of the disease (recovery or remission) or death. Results-Six patients were included in the study. Each patient had histopathological or arteriographic evidence of vasculitis and was infected with actively replicating HBV. Ah patients were alive at the end of the study and no longer presented clinical or laboratory evidence of systemic vasculitis. HBeAg/anti-HBeAb seroconversion was observed in four patients (66.6%) and HBsAg/anti-HBsAb in 3/6 (50%). Two patients are still being treated with INFa2b because of chronic active hepatitis. C Conclusions-It is considered that this new therapeutic approach to HBV-related PAN effectively cured systemic vasculitis and was associated with control of HBV infections. Antiviral therapy may have a role to play as the first line treatment regime of virus-induced vasculitis.
引用
收藏
页码:334 / 337
页数:4
相关论文
共 15 条
  • [1] BLETRY O, 1982, NOUV PRESSE MED, V11, P2827
  • [2] GUILLEVIN L, 1993, J RHEUMATOL, V20, P289
  • [3] GUILLEVIN L, 1988, BRIT J RHEUMATOL, V27, P258
  • [4] GUILLEVIN L, 1991, J RHEUMATOL, V18, P567
  • [5] GUILLEVIN L, 1992, ANN MED INTERNE, V143, P63
  • [6] COMPARISON OF PROPERTIES OF WOODCHUCK HEPATITIS-VIRUS AND HUMAN HEPATITIS-B VIRUS ENDOGENOUS DNA-POLYMERASES
    HANTZ, O
    OOKA, T
    VITVITSKI, L
    PICHOUD, C
    TREPO, C
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 25 (02) : 242 - 246
  • [7] MIXED CRYOGLOBULINEMIA RESPONSIVE TO INTERFERON-ALPHA
    KNOX, TA
    HILLYER, CD
    KAPLAN, MM
    BERKMAN, EM
    [J]. AMERICAN JOURNAL OF MEDICINE, 1991, 91 (05) : 554 - 555
  • [8] DELETERIOUS EFFECT OF PREDNISOLONE IN HBSAG-POSITIVE CHRONIC ACTIVE HEPATITIS
    LAM, KC
    LAI, CL
    NG, RP
    TREPO, C
    WU, PC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (07) : 380 - 386
  • [9] LIGHTFOOT RW, 1990, ARTHRITIS RHEUM, V33, P1088
  • [10] HEPATITIS-B-ASSOCIATED POLYARTERITIS NODOSA IN ALASKAN ESKIMOS - CLINICAL AND EPIDEMIOLOGIC FEATURES AND LONG-TERM FOLLOW-UP
    MCMAHON, BJ
    HEYWARD, WL
    TEMPLIN, DW
    CLEMENT, D
    LANIER, AP
    [J]. HEPATOLOGY, 1989, 9 (01) : 97 - 101